molecules of the month


BRD4 (BD1/2) BET bromodomain inhibitor

wound-heal. at 1 mpk QD, bell-shaped pharm.

from phenotypic screen (MDM2 inhibitor hit)

Nat. Chem. Biol., Jan. 18, 2021

Novartis (NIBR), Basel, CH

Chemical structure of molecule NVS-BET-1
1 min read

The Novartis BET bromodomain inhibitor, NVS-BET-1, is a new chemotype of BRD4 (BD1 and BD2) inhibitor. While we recently highlighted a few high-profile, selective bromodomain inhibitors from AbbVie and GSK, the Novartis team took a different approach to reaching their molecules. The Novartis team was looking for mechanisms that influence keratinocyte differentiation to treat wound healing, and identified BET inhibitors in a phenotypic screen. Interestingly, their proprietary matter emerged from a BRD4 biochemical screen that identified a totally unrelated p53-MDM2 inhibitor as a moderately potent hit. Optimization led to NVS-BET-1 which potently influences wound healing when administered orally at doses as low as 1 mg/kg. The wound-healing effects however, were lost at higher concentrations, recapitulating the “bell-shaped” dose-response curves from…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: